Uniklinikum Erlangen | 65 in transradial versus transfemoral access - Results from the German Austrian ABSORB registry (GABIR). Cardiovasc Revasc Med. 2021 Nov 24:S15538389(21)00749-1. 59. Wiebe J, Hofmann FJ, Dörr O, Bauer T, Boeder N, Liebetrau C, Blachutzik F, Möllmann H, Elsässer A, Achenbach S, Hamm CW, Nef HM. Five-year follow-up of patients who underwent everolimus-eluting bioresorbable scaffold implantation. Catheter Cardiovasc Interv. 2021 Jan 1;97(1):56-62. 60. Wiebe J, Hofmann FJ, West N, Baumbach A, Carrie D, Bermudez EP, Cayla G, Hernandez FH, de la Torre Hernandez JM, Koning R, Loi B, Moscarella E, Tarantini G, Zaman A, Lober C, Riemer T, Achenbach S, Hamm CW, Nef HM; European ABSORB Consortium (EAC) investigators. Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice -results from the European Absorb Consortium. Catheter Cardiovasc Interv. 2021 Aug 31. doi: 10.1002/ccd.29932. Epub ahead of print. 61. Willett J, Achenbach S, Pinto FJ, Poppas A, Elkind MSV. The Tobacco Endgame: Eradicating a worsening epidemic. A joint opinion from the American Heart Association, World Heart Federation, American College of Cardiology, and the European Society of Cardiology. J Am Coll Cardiol. 2021 Jul 6;78(1):77-81. 62. Wunderlich NC, Landendinger M, Arnold M, Achenbach S, Swaans MJ, Siegel RJ, Ho SY. State-ofthe-art review: anatomical and imaging considerations during transcatheter tricuspid valve repair using an annuloplasty approach. Front Cardiovasc Med. 2021 Feb 5;8:619605. 63. Zhang L, Olalere D, Mayrhofer T, Bittner DO, Emami H, Meyersohn NM, Puchner SB, Abidov A, Moloo J, Dolor RJ, Mark DB, Ferencik M, Hoffmann U, Douglas PS, Lu MT. Differences in cardiovascular risk, coronary artery disease, and cardiac events between black and white individuals enrolled in the PROMISE Trial. JAMA Cardiol. 2021 Dec 22. doi: 10.1001/jamacardio.2021.5340. Epub ahead of print.
RkJQdWJsaXNoZXIy ODIyMTAw